52 results about "Immune thrombocytopenia" patented technology

The invention relates to novel medical application of anhydroicaritin, particularly to application of anhydroicaritin in preparing a drug for treating or preventing thrombopenia, and belongs to the field of medicines. In order to overcome the technical defects that, in the prior art, the thrombopenia therapeutic drug is unabiding in therapeutic effect, high in possibility of recidivation during drug discontinuance and high in side effect, the invention provides a therapeutic drug containing anhydroicaritin. The therapeutic drug can greatly improve the platelet level of a parent when being used for treating thrombopenia, particularly immune thrombopenia, and has an obvious therapeutic effect; the therapeutic drug further has the obvious therapeutic effect on treating thrombopenia caused by myelosuppression; when being used for treating thrombopenia, anhydroicaritin has the advantages of being obvious in curative effect, low in treatment cost and little in toxic and side effects, and the therapeutic drug is quite suitable for clinical popularization and application.

A method is disclosed for the treatment of human subjects diagnosed with immune thrombocytopenia (ITP). The method comprises administering to a human subject a human neonatal Fc receptor (hFcRn) antagonist, optionally in combination with standard-of-care ITP treatment. In certain embodiments, the hFcRn antagonist is efgartigimod (ARGX-113). Standard-of-care ITP treatment may comprise administration of corticosteroids, immunosuppressants, and/or thrombopoietin receptor (TPO-R) agonists.

The invention belongs to blood platelet clinical test and research and relates to a cytometric bead method for detecting blood platelet autoantibodies of immune thrombocytopenia. The cytometric bead method for detecting blood platelet autoantibodies of immune thrombocytopenia is high in sensitivity and specificity. The method comprises encapsulating beads through anti-human platelet membrane glycoprotein monoclonal antibodies, incubating platelet lysate and the encapsulated beads, and then adding in phycoerythrin marked goat antihuman immune globulin polyclonal antibodies to perform flow cytometry. If autoantibodies exist on the surface of platelets, a bead-platelet membrane glycoprotein monoclonal antibody-platelet membrane glycoprotein autoantibody-phycoerythrin marked goat antihuman immune globulin polyclonal antibody composite structure can be formed and embodied as increase of fluorescence intensity of detecting beads. The cytometric bead method for detecting blood platelet autoantibodies of immune thrombocytopenia is convenient to operate, mature in technology, high in sensitivity of blood platelet autoantibody detection and conductive to fundamental experimental research on platelet antibodies.

The thrombocytopenia treating Chinese medicine is orally taken preparation prepared with Chinese medicinal materials including notoginseng, bletilla tuber, cogongrass rhizome, and lotus root charcoal. Clinical test shows that the Chinese medicine of the present invention has obvious thrombocyte increasing and clinical symptom remitting effect on light and medium thrombocytopenia, including primary thrombocytopenia purpura caused by some medicine and has no toxic side effect. On serious thrombocytopenia, the present invention may assist chemical medicine treatment and reduce toxic side effect.

The present application provides compositions and methods useful for detecting and monitoring immune thrombocytopenia.

The invention relates to a traditional Chinese medicine composition for treating idiopathic thrombocytopenic purpura. The traditional Chinese medicine composition is prepared from the following raw pharmaceutical materials in parts by weight: 20-28 parts of raw milkvetch root, 15-20 parts of prepared ligustrum lucidum, 10-15 parts of atractylodes macrocephala, 12-18 parts of raw rehmannia root, 15-20 parts of dodder seed, 12-18 parts of tree peony bark, 12-18 parts of Jiangnan herba selaginellae, 12-18 parts of herba agrimoniae, 12-18 parts of aizoon stonecrop and 4-8 parts of prepared liquorice root. The invention further provides application of the traditional Chinese medicine composition. The traditional Chinese medicine composition has the advantages that the compatibility of the traditional Chinese medicine composition disclosed by the invention accords with the principle of monarch-and-minister-and-assistant-and-guide of the traditional Chinese medicine, the traditional Chinese medicine composition can effectively control the bleeding symptom of a sufferer, improve the quality of life and increase the number of platelets and has a remarkable treatment effect on idiopathic thrombocytopenic purpura, and no adverse reaction is caused, so that the traditional Chinese medicine composition has broad development and application prospects and is suitable for further popularization and application.

The invention discloses application of an artemisinin compound in preparation of drugs for treating ITP. It is unexpectedly discovered in clinical trials that blood platelet count holding time can beprolonged when drugs of artemisinin, especially artesunate or dihydroartemisinin treat patients with immune thrombocytopenia and patients with relapse of the immune thrombocytopenia, and it is indicated that the artemisinin drugs have a good therapeutic effect on the immune thrombocytopenia. Further studies show that the combination of the artemisinin drugs and other drugs, such as the combinationof the artemisinin drugs and glucocorticoids, can further reduce the dosage of glucocorticoid, gamma globulin and the like for treatment, thereby reducing the treatment cost of the patients and reducing the probability of significant complications. Reticulocytes as a toxicity sensitive index of the artemisinin drugs are strictly observed by the inventor, it is found that no significant differenceexists before and after the treatment, and it is further showed that the artemisinin drugs have good safety.

The invention relates to new use of a drug, in particular to a G-CSF regulating the ratio of Th1/Th2 cells of PBMCs in an ITP patient to treat ITP. In vitro experiments demonstrate that the G-CSF canreduce the Th1/Th2 ratio in the ITP patient in a dose-dependent manner. The decrease in the ratio of T-bet/GATA-3 demonstrates that the G-CSF can reduce the Th1/Th2 ratio indirectly. The study shows for the first time the potential treatment effect of the G-CSF on the ITP patient.

The invention discloses a traditional Chinese medicine composition for treating primary immune thrombocytopenia. Active ingredients of the traditional Chinese medicine composition are prepared from the following crude drugs in parts by weight: 50-70 parts of hairyvein agrimonia herbs, 5-15 parts of platycodon roots, 5-15 parts of smoked plums, 5-15 parts of common aucklandia roots, 10-30 parts ofprepared radix glycyrrhizae,10-30 pats of parched white atractylodes rhizomes, 10-30 parts of debark peony roots, 10- 30 parts of areca seeds, 20-40 parts of fried coix seeds, 20-40 parts of poria cocos, 20-40 parts of atrina glass, 20-40 parts of milkvetch roots, 20-40 parts of codonopsis pilosula, 5-15 parts of tortoise-plastron glues and 5-15 parts of largetrifoliolious bugbane rhizomes. The invention has effects in stopping bleeding, increasing platelets and regulating immunity, and is fast in taking effect, exact in curative effect, not easy to relapse and free of toxic side effects. After clinical practice, the traditional Chinese medicine composition shows a cure rate as high as 98%, and the traditional Chinese medicine composition is the choice drug for treating the primary immunethrombocytopenia.

The invention discloses a preparation method for human-mouse chimeric monoclonal antibodies of human CD20. SPF-level female Balb/c mice 6-12 weeks old are employed, and the immunization flows are the same as immunization flows of general serum preparation; the immuned mice are subjected to pretreatment, B cells and myeloma cells are subjected to cell fusion through a PEG method; HAT is employed for selective culture, hybridomas are obtained; the cell culture supernatant fluid is detected, and positive clone screening is carried out; hybridoma cloning is carried out; cryopreservation and recovery of the hybridomas are carried out; human-mouse chimeric monoclonal antibodies of human CD20 are produced for a large scale. An embodiment employing a small dose of rituximab for treating immune thrombocytopenia supports that combination of rituximab and other medicines may obtain better effects in clinic application compared with a single medicine, has good treatment effects in immune thrombocytopenia treatment, has small adverse reactions, and can be employed as an effective second-line treatment means.

The present invention relates to the use of suppressive macrophage or dendritic cells (activated with C-reactive protein or CRP-related compounds), for the treatment of various disease states and conditions associated with immune thrombocytopenic purpura (ITP) and/or systemic lupus erythematosus (SLE), including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein. In another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with systemic lupus erythematosus or ITP will have an outbreak is an additional aspect of the present invention. In the case of ITP, methods of the present invention are used to increase platelet counts in the treated patient. In addition, in the case of ITP, the present invention relates to the use of CRP or a CRP-related compound in the absence of suppressive macrophages for the treatment of ITP.

The invention aims at providing a traditional Chinese medicine for treating Yin-deficiency and excessive fire type children primary immune thrombocytopenia. The traditional Chinese medicine is prepared from the following crude drugs by weight: 6 to 15g of radix rehmanniae recen, 6 to 15g of cortex moutan radicis, 6 to 15g of fructus lycii, 6 to 15g of fructus schisandrae chinensis, 6 to 15g of herba agrimoniae, 5 to 12g of lithospermum carbon, 5 to 12g of rubia cordifolia, 5 to 12g of oroxyli, 6 to 15g of radix isatidis, and 2 to 6g of honey-fried liquorice root. The traditional Chinese medicine has the advantages that by adopting the pure traditional Chinese medicines, the components are mutually complementary; the effects of nourishing Yin and clearing heat as well as cooling blood and calming meridians are realized; by reducing the repeated infection times of a patient and regulating the immunity, the platelets are stabilized within the normal range for a long time, the bleeding frequency is reduced, the treatment effect is good, and the safety in use is realized; the traditional Chinese medicine is an innovation in medicines for treating Yin-deficiency and excessive fire type children primary immune thrombocytopenia; the economic and social effects are obvious.